Please login to the form below
EC approves GSK's Tyverb for breast cancer
The European Commission (EC) has approved an additional use of GlaxoSmithKline's (GSK) Tyverb (lapatinib) as a treatment for breast cancer
The European Commission (EC) has approved an additional use of GlaxoSmithKline's (GSK) Tyverb (lapatinib), in combination with an aromatase inhibitor, as a treatment for post-menopausal women with hormone receptor-positive, HER2 over-expressing metastatic breast cancer and for whom chemotherapy is currently not intended.
The approval follows a positive recommendation by the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) in February 2010.
According to a consensus forecast compiled by Thomson Reuters, sales of Tyverb in the US (where the drug is sold as Tykerb), are expected to reach around $375m in 2014.
Earlier this month, draft guidance issued by the UK's National Institute for Health and Clinical Excellence (NICE), recommended against the use of Tyverb outside of clinical trials.
Share
Related Hub content
Subscribe to our email news alerts
- Contagious Conversations: Exploring Infectious Disease in the Digital Age
- Austrian State Secretary to speak at FlyPharma Europe 2023
- Further data for AstraZeneca/Daichii Sankyo’s Enhertu for breast cancer requested by NICE
- Gritstone Bio receives $433m BARDA contract for COVID-19 vaccine candidate
- EDX Medical Group develops multi-disease 'point-of-care' rapid tests for cancer, infections and cardiovascular conditions
- ScreenPoint Medical to showcase AI software at European scientific meeting
No results were found
PMHub
nzyme
The nzyme group focuses on the three fundamentals that enable full patient access - Education, Access & Activation. Our specialist...
Latest intelligence
- The importance of accelerating clinical trial diversity
- Diversity shouldn’t be an afterthought – it’s an investment in the credibility of scientific endeavour...
- Digital Opinion Leaders: The Role of Influencers in Medical Communications
- There are many informed, knowledgeable HCPs who talk about a disease state online, but not all of them are influencers. This paper explores who digital opinion leaders are and how...
- Creating Hope Though Action – World Suicide Prevention Day
- At Mednet Group, we believe that actions speak louder than words. That's why we're getting behind this year's Suicide Prevention Day campaign of 'creating hope through action'....
